ACM
ATXS

Aquatic Capital Management’s Astria Therapeutics ATXS Stock Holding History

Aquatic Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-800
Closed -$7K – 1238
2023
Q2 		$7K Buy
+800
New +$9.23K ﹤0.01% 1220

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Aquatic Capital Management's ATXS Position: Q3 2023 in Review

Aquatic Capital Management sold out of Astria Therapeutics (ATXS) in Q3 2023, closing a stake of 800 shares — an estimated $7K sold.

Aquatic Capital Management first reported a position in ATXS in Q2 2023 and held it in 1 quarter. The position peaked at $7K in Q2 2023. 68 funds tracked by Wall St. Rank hold ATXS as of Q3 2023.

  • Aquatic Capital Management reported no remaining Astria Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 800 Astria Therapeutics shares in Q3 2023, an estimated $7K.
  • Aquatic Capital Management first reported a position in Astria Therapeutics in Q2 2023 and held it in 1 quarter.
  • Aquatic Capital Management's Astria Therapeutics position peaked at $7K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2023.

Based on Aquatic Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.